Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]
Palatin Technologies, Inc. (PTN)
NASDAQ:AMEX Investor Relations:
palatin.com/investors/overview
Company Research
Source: Yahoo! Finance
Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Patient enrollment completed October 2024 Topline results expected 1Q calendar year 2025 Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compounds General obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesity Dry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs: Investment bank engaged as a financial advisor to explore strategic options for non-obesity programs Teleconference and Webcast to be held on November 14, 2024 , at 11:00 AM ET CRANBURY, N.J. Nov. 14, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced oper
Show less
Read more
Impact Snapshot
Event Time:
PTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTN alerts
High impacting Palatin Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
PTN
News
- Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy [Yahoo! Finance]Yahoo! Finance
- Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyPR Newswire
- Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsPR Newswire
- Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis [Yahoo! Finance]Yahoo! Finance
PTN
Earnings
- 11/14/24 - Beat
PTN
Sec Filings
- 12/16/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- PTN's page on the SEC website